Amr Morsy, MD
Interventional Pain Medicine · Rockwall, TXNPI 1447233895
Payments from drug & device makers
Across 749 payments — averaging $24.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$4K
- Abbott$4K
- Spinal Simplicity, LLC$2K
- AbbVie$1K
- Stryker$932
- Scilex Pharmaceuticals Inc.$856
- plus $6K from 44 others
What the payments were for
- Speaking & faculty fees$540%
- Travel & lodging$4,10923%
- Food & beverage$13,92876%
- Education$1541%
- Gifts$150%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Proclaim Family of SCS IPGs$1,255
- mild Device Kit$1,218
- INTELLIS ADAPTIVESTIM$938
- VANTA ADAPTIVESTIM$774
- INTELLIS$599
- PROCLAIM$456
- HA MINUTEMAN G3-R$425
- Intracept$327
- UBRELVY$247
- ETERNA$150
- Senza Spinal Cord Stimulation System$149
- SYNCHROMED$148
- Octrode SCS Leads$140
- PNS FREEDOM-4A PERMANENT NEUROSTIMULATOR RECEIVER KIT CHANNEL A$130
- Neuromodulation Dspsbls and Accs$130
- Qutenza$128
- NURTEC ODT$125
- QULIPTA$125
- Omnia$111
How this compares
$18,260 in reported general payments places this provider in the 75th percentile of 287 interventional pain medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 172 | $164,067 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 2,047 | $69,849 |
| Buprenorphine | 304 | $63,240 |
| Xtampza ErOxycodone Myristate | 101 | $51,332 |
| BelbucaBuprenorphine Hcl | 50 | $31,373 |
| RoxybondOxycodone Hcl | 16 | $24,827 |
| Nucynta ErTapentadol Hcl | 20 | $19,065 |
| Nurtec OdtRimegepant Sulfate | 13 | $17,004 |
| MounjaroTirzepatide | 13 | $15,834 |
| MovantikNaloxegol Oxalate | 37 | $15,314 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 339 | $12,417 |
| ZtlidoLidocaine | 32 | $12,325 |
| Pregabalin | 430 | $10,828 |
| NucyntaTapentadol Hcl | 11 | $10,679 |
| Gabapentin | 913 | $10,664 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca, Nucynta Er, Nucynta | $826 | $112,448182 claims |
| Protega Pharmaceutials IncRoxybond | $96 | $24,82716 claims |
| PfizerNurtec Odt | $460 | $17,00413 claims |
| Lilly USA, LLCMounjaro | $16 | $15,83413 claims |
| Redhill Biopharma Inc.Movantik | $16 | $15,31437 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $856 | $12,32532 claims |
| Upsher-smith Laboratories LLCTopiramate | $21 | $309122 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 287 interventional pain medicine providers in Texas.
Other interventional pain medicine in Rockwall
- Tibor RaczRockwall$22K
- Gabor RaczLubbock$3M
- Pankaj MehtaKilleen$2.2M
- Genaro GutierrezAustin$1.3M
- Chad StephensSouthlake$1.1M
- Ioannis SkaribasHouston$979K
- Duane GriffithTyler$730K
- Brannon FrankAustin$698K
- Robert WillsRound Rock$692K
- Ankur KhoslaShenandoah$511K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.